131 related articles for article (PubMed ID: 10427858)
1. [New antithrombotic oligosaccharides].
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
[TBL] [Abstract][Full Text] [Related]
2. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
[TBL] [Abstract][Full Text] [Related]
4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
6. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
[TBL] [Abstract][Full Text] [Related]
8. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs.
Petitou M; Lormeau JC; Choay J
Nature; 1991 Apr; 350(6319 Suppl):30-3. PubMed ID: 2017262
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of new synthetic heparin mimetics.
Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
[TBL] [Abstract][Full Text] [Related]
10. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
11. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans.
Noti C; Seeberger PH
Chem Biol; 2005 Jul; 12(7):731-56. PubMed ID: 16039522
[TBL] [Abstract][Full Text] [Related]
12. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
[TBL] [Abstract][Full Text] [Related]
13. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
14. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
Turk B; Brieditis I; Bock SC; Olson ST; Björk I
Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
[TBL] [Abstract][Full Text] [Related]
15. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Petitou M; van Boeckel CA
Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
Hobbelen PM; van Dinther TG; Vogel GM; van Boeckel CA; Moelker HC; Meuleman DG
Thromb Haemost; 1990 Apr; 63(2):265-70. PubMed ID: 2363127
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
18. Selective and dual action orally active inhibitors of thrombin and factor Xa.
Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
[TBL] [Abstract][Full Text] [Related]
19. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
Hérault JP; Perrin B; Jongbloet C; Pflieger AM; Bernat A; Herbert JM
Thromb Haemost; 2000 Oct; 84(4):668-74. PubMed ID: 11057868
[TBL] [Abstract][Full Text] [Related]
20. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]